학술논문

29 - Six versus three-weekly pembrolizumab: as well-tolerated?
Document Type
Article
Source
Lung Cancer (01695002). Jun2021:Supplement 1, Vol. 156, pS11-S12. 2p.
Subject
*PEMBROLIZUMAB
Language
ISSN
0169-5002